Science & Technology Former EMBL staff scientist founds a start-up – DenovAI – for broader, faster and cheaper antibody discovery using advanced machine learning and computational biophysics.
2023
sciencescience-technology
Science & Technology By screening hundreds of sybodies (synthetic mini-antibodies), scientists have identified one that might stop SARS-CoV-2 from infecting human cells. This work, which holds promise for treating COVID-19, was conducted by EMBL Hamburg and collaborators from the Centre for Structural Systems Biology…
2020
sciencescience-technology
Science & Technology Scientists hope that a legacy of the novel coronavirus in recovered COVID-19 patients – antibodies in their blood – could lead to drugs to treat others. The Merten group at EMBL Heidelberg has pivoted its microfluidics platform to support the search for neutralising antibodies that could…
2020
sciencescience-technology
Science & Technology Scientists at EMBL Hamburg and Karolinska Institutet Stockholm aim to find synthetic antibodies – known as nanobodies – that bind a surface protein of the novel SARS-CoV-2 coronavirus. Nanobodies could prevent the virus from entering human cells and causing COVID-19.
2020
sciencescience-technology
Lab MattersScience & Technology The new EMBL spinoff company Araxa Biosciences GmbH aims to set new standards for the development of antibody-based therapeutics and diagnostics
2020
lab-mattersscience-technology
Lab MattersScience & Technology New EMBL spinoff company Velabs Therapeutics aims to speed up discovery of therapeutic antibodies
2018
lab-mattersscience-technology
No matching posts found
Looking for past print editions of EMBLetc.? Browse our archive, going back 20 years.
EMBLetc. archive
